menu search

ANIP / ANI Pharmaceuticals Is Undervalued When Considering Their Unadvertised Pipeline

ANI Pharmaceuticals Is Undervalued When Considering Their Unadvertised Pipeline
ANIP Pharmaceuticals has not yet published a pipeline of products under development or out-licensed, leaving investors in the dark about future revenue opportunities. The company has a range of drugs in various stages of development, including treatments for rheumatic disorders, nervous system conditions, respiratory diseases, and metabolic disorders. Key drugs in phase 3 trials include a treatment for hypoactive sexual desire disorder and several cardiovascular treatments, with significant clinical trial results expected by October 2023. Read More
Posted: Jul 5 2023, 00:51
Author Name: Seeking Alpha
Views: 080975

ANIP News  

ANI Pharmaceuticals (ANIP) Stock Drops Despite Market Gains: Important Facts to Note

By Zacks Investment Research
November 1, 2023

ANI Pharmaceuticals (ANIP) Stock Drops Despite Market Gains: Important Facts to Note

ANI Pharmaceuticals (ANIP) closed at $61.66 in the latest trading session, marking a -0.13% move from the prior day. more_horizontal

ANI Pharmaceuticals to Discuss Third Quarter 2023 Financial Results on November 8, 2023, at 8:30 a.m. ET

By GlobeNewsWire
October 25, 2023

ANI Pharmaceuticals to Discuss Third Quarter 2023 Financial Results on November 8, 2023, at 8:30 a.m. ET

BAUDETTE, Minn., Oct. 25, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the more_horizontal

ANI Pharmaceuticals (ANIP) Increases Despite Market Slip: Here's What You Need to Know

By Zacks Investment Research
October 20, 2023

ANI Pharmaceuticals (ANIP) Increases Despite Market Slip: Here's What You Need to Know

ANI Pharmaceuticals (ANIP) closed at $57.44 in the latest trading session, marking a +0.23% move from the prior day. more_horizontal

ANI Pharmaceuticals (ANIP) Stock Sinks As Market Gains: Here's Why

By Zacks Investment Research
October 6, 2023

ANI Pharmaceuticals (ANIP) Stock Sinks As Market Gains: Here's Why

The latest trading day saw ANI Pharmaceuticals (ANIP) settling at $58.39, representing a -0.41% change from its previous close. more_horizontal

Here's Why You Should Add ANI Pharmaceuticals (ANIP) to Your Portfolio

By Zacks Investment Research
September 11, 2023

Here's Why You Should Add ANI Pharmaceuticals (ANIP) to Your Portfolio

ANI Pharmaceuticals (ANIP), a top-ranked stock, has a diverse portfolio of rare disease and generic medicines. Its Purified Cortrophin Gel is witnessi more_horizontal

ANI (ANIP) Is a Great Choice for 'Trend' Investors, Here's Why

By Zacks Investment Research
September 8, 2023

ANI (ANIP) Is a Great Choice for 'Trend' Investors, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, ANI (ANIP) could be a great choice. It is one of the several more_horizontal

What Makes ANI (ANIP) a New Strong Buy Stock

By Zacks Investment Research
August 25, 2023

What Makes ANI (ANIP) a New Strong Buy Stock

ANI (ANIP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). more_horizontal

New Strong Buy Stocks for August 25th

By Zacks Investment Research
August 25, 2023

New Strong Buy Stocks for August 25th

ANIP, NVMI, AZPN, GRNT and CVLG have been added to the Zacks Rank #1 (Strong Buy) List on August 25, 2023. more_horizontal


Search within

Pages Search Results: